Compare Illumina, Inc. (ILMN) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs S&P500 ETF — how do they compare? Illumina, Inc. trades at $273.58 (market cap $39.95B), while S&P500 ETF trades at $776.06 (market cap $821.54B). The key difference: S&P500 ETF is far larger — about 20.6× Illumina, Inc.'s market cap, and S&P500 ETF is more actively traded (40,070,358 versus 3,169,503). Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and S&P500 ETF for 205 Days on average.
| ILMN | SPY | |
|---|---|---|
Market Cap | $39.95B | $821.54B |
Volume | 3,169,503 | 40,070,358 |
Sector | Health | — |
52-Week High | $293.69 | $779.14 |
52-Week Low | $91.00 | $631.99 |
Typical Hold Time | 83 Days | 205 Days |
Enterprise Value | $41.31B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
SPY, tracking the S&P 500, trades at $775.78, down 0.19% on the day amid a mixed technical backdrop with a bullish moving average signal but neutral oscillators. The ETF shows no available fundamental ratios in this snapshot, and a dividend of $1.89 is scheduled for payment in October 2026. Recent news highlights market volatility, with articles discussing valuation concerns and sector rotations.
The outlook for SPY hinges on broader market trends, with technical support near $771 offering a cushion. Risks include potential earnings growth slowdowns and macroeconomic pressures, but the bullish moving average alignment suggests underlying strength for long-term investors focused on U.S. equity exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
